原發(fā)性肝癌是全球范圍內高發(fā)病率且高致死率的惡性腫瘤之一。在原發(fā)性肝癌治療中，單一藥物往往受到不良反應和耐藥性的限制，聯(lián)合用藥可以發(fā)揮多機制協(xié)同作用增加療效，降低毒副作用，延緩耐藥性。中藥單體具有良好的抗肝癌作用，較低的毒副作用以及可以拮抗化療藥物對正常組織細胞的損害等優(yōu)點常被用于與化療藥物聯(lián)合應用治療肝癌。納米制劑可以使聯(lián)合使用的藥物在吸收分布上呈現(xiàn)出同步性，更好地發(fā)揮聯(lián)用藥物的協(xié)同作用，常被用于聯(lián)用藥物的負載和遞送。對化療藥物聯(lián)合中藥單體的優(yōu)勢、納米共載的優(yōu)勢以及用于肝癌治療的中藥單體與化療藥物共載納米制劑研究進展進行了綜述，為聯(lián)合用藥抗肝癌的研究提供參考。

Primary liver cancer is one of the malignant tumors with high incidence and mortality rates worldwide. In its treatment, single-drug therapies are often limited by toxic side effects and drug resistance. Combination therapy can exert multi-mechanism synergistic effects to enhance efficacy, reduce toxic side effects, and delay the development of drug resistance. Traditional Chinese medicine (TCM) monomers, which exhibit potent anti-liver cancer activity, lower toxicity, and the ability to counteract chemotherapy-induced damage to normal tissues, are frequently used in combination with chemotherapeutic drugs for liver cancer treatment. Nano-formulations enable synchronized absorption and distribution of combined drugs, thereby enhancing their synergistic effects, and are widely used for the loading and delivery of co-administered drugs. This article reviews the advantages of combining chemotherapeutic drugs with TCM monomers, the benefits of nano co-delivery, and recent research progress in co-delivery nano-formulations of TCM monomers and chemotherapeutic drugs for liver cancer treatment, aiming to provide insights for advancing research on combination therapy against liver cancer.

R286.2

廣西自然科學基金資助項目（2022GXNSFDA035063）；廣西自然科學基金資助項目（2023GXNSFAA026366）；國家自然科學基金資助項目（82360818）；國家自然科學基金資助項目（81960756）